HspB8 prevents aberrant phase transitions of FUS by chaperoning its folded RNA binding domain

  1. Edgar E Boczek
  2. Julius Fürsch
  3. Marie Laura Niedermeier
  4. Louise Jawerth
  5. Marcus Jahnel
  6. Martine Ruer-Gruß
  7. Kai-Michael Kammer
  8. Peter Heid
  9. Laura Mediani
  10. Jie Wang
  11. Xiao Yan
  12. Andrej Pozniakovski
  13. Ina Poser
  14. Daniel Mateju
  15. Lars Hubatsch
  16. Serena Carra
  17. Dr. Simon Alberti
  18. Anthony A Hyman
  19. Florian Stengel  Is a corresponding author
  1. Max Planck Institute of Molecular Cell Biology and Genetics, Germany
  2. University of Konstanz, Germany
  3. Max Planck Institute for the Physics of Complex Systems, Germany
  4. Biotec, TU Dresden, Germany
  5. University of Modena and Reggio Emilia, Italy

Abstract

Aberrant liquid-to-solid phase transitions of biomolecular condensates have been linked to various neurodegenerative diseases. However, the underlying molecular interactions that drive aging remain enigmatic. Here, we develop quantitative time-resolved crosslinking mass spectrometry to monitor protein interactions and dynamics inside condensates formed by the protein fused in sarcoma (FUS). We identify misfolding of the RNA recognition motif (RRM) of FUS as a key driver of condensate ageing. We demonstrate that the small heat shock protein HspB8 partitions into FUS condensates via its intrinsically disordered domain and prevents condensate hardening via condensate-specific interactions that are mediated by its α-crystallin domain (αCD). These αCD-mediated interactions are altered in a disease-associated mutant of HspB8, which abrogates the ability of HspB8 to prevent condensate hardening. We propose that stabilizing aggregation-prone folded RNA-binding domains inside condensates by molecular chaperones may be a general mechanism to prevent aberrant phase transitions.

Data availability

All data generated or analysed during this study are included in this published article (and its supplementary information files). The MS data (raw files, xQuest, xTract and in-house quantitation output files) have been deposited to the ProteomeXchange Consortium via the PRIDE (60) partner repository with the dataset identifier PXD021114 (Username: reviewer33076@ebi.ac.uk; Password: 5atfkbP8) and PXD021115 (Username: reviewer54149@ebi.ac.uk; Password: UZW7Gnr5).

The following data sets were generated

Article and author information

Author details

  1. Edgar E Boczek

    Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany
    Competing interests
    Edgar E Boczek, is currently an employee of Dewpoint Therapeutics..
  2. Julius Fürsch

    Department of Biology, University of Konstanz, Konstanz, Germany
    Competing interests
    No competing interests declared.
  3. Marie Laura Niedermeier

    Department of Biology, University of Konstanz, Konstanz, Germany
    Competing interests
    No competing interests declared.
  4. Louise Jawerth

    Max Planck Institute for the Physics of Complex Systems, Dresden, Germany
    Competing interests
    No competing interests declared.
  5. Marcus Jahnel

    Biophysics, Biotec, TU Dresden, Dresden, Germany
    Competing interests
    No competing interests declared.
  6. Martine Ruer-Gruß

    Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany
    Competing interests
    No competing interests declared.
  7. Kai-Michael Kammer

    Department of Biology, University of Konstanz, Konstanz, Germany
    Competing interests
    No competing interests declared.
  8. Peter Heid

    Department of Biology, University of Konstanz, Konstanz, Germany
    Competing interests
    No competing interests declared.
  9. Laura Mediani

    University of Modena and Reggio Emilia, Modena, Italy
    Competing interests
    No competing interests declared.
  10. Jie Wang

    Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany
    Competing interests
    No competing interests declared.
  11. Xiao Yan

    Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany
    Competing interests
    No competing interests declared.
  12. Andrej Pozniakovski

    Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany
    Competing interests
    No competing interests declared.
  13. Ina Poser

    Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany
    Competing interests
    Ina Poser, is currently an employee of Dewpoint Therapeutics.
  14. Daniel Mateju

    Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany
    Competing interests
    No competing interests declared.
  15. Lars Hubatsch

    Max Planck Institute for the Physics of Complex Systems, Dresden, Germany
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1934-7437
  16. Serena Carra

    University of Modena and Reggio Emilia, Modena, Italy
    Competing interests
    No competing interests declared.
  17. Dr. Simon Alberti

    Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany
    Competing interests
    Dr. Simon Alberti, is a shareholder, consultant and member of the scientific advisory board for Dewpoint Therapeutics..
  18. Anthony A Hyman

    Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany
    Competing interests
    Anthony A Hyman, is cofounder, shareholder, consultant and member of the scientific advisory board for Dewpoint Therapeutics..
  19. Florian Stengel

    Department of Biology, University of Konstanz, Konstanz, Germany
    For correspondence
    Florian.Stengel@uni-konstanz.de
    Competing interests
    Florian Stengel, is a consultant and member of the scientific advisory board for Dewpoint Therapeutics..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1447-4509

Funding

Deutsche Forschungsgemeinschaft (STE 2517/1-1)

  • Florian Stengel

Konstanz Research School Chemical Biology (Chemicals and small Equipment Purchase)

  • Florian Stengel

Deutsche Forschungsgemeinschaft (Cluster of Excellence Physics of Life"")

  • Dr. Simon Alberti

Deutsche Forschungsgemeinschaft (Cluster of Excellence Physics of Life"")

  • Anthony A Hyman

EU Joint Programme – Neurodegenerative Disease Research (Neurodegenerative Disease Research (JPND))

  • Serena Carra

EU Joint Programme – Neurodegenerative Disease Research (Neurodegenerative Disease Research (JPND))

  • Dr. Simon Alberti

AriSLA Foundation (Granulopathy and MLOpathy)

  • Serena Carra

MAECI (Dissolve_ALS)

  • Serena Carra

MIUR (E91I18001480001)

  • Serena Carra

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2021, Boczek et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,175
    views
  • 567
    downloads
  • 53
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Edgar E Boczek
  2. Julius Fürsch
  3. Marie Laura Niedermeier
  4. Louise Jawerth
  5. Marcus Jahnel
  6. Martine Ruer-Gruß
  7. Kai-Michael Kammer
  8. Peter Heid
  9. Laura Mediani
  10. Jie Wang
  11. Xiao Yan
  12. Andrej Pozniakovski
  13. Ina Poser
  14. Daniel Mateju
  15. Lars Hubatsch
  16. Serena Carra
  17. Dr. Simon Alberti
  18. Anthony A Hyman
  19. Florian Stengel
(2021)
HspB8 prevents aberrant phase transitions of FUS by chaperoning its folded RNA binding domain
eLife 10:e69377.
https://doi.org/10.7554/eLife.69377

Share this article

https://doi.org/10.7554/eLife.69377

Further reading

    1. Biochemistry and Chemical Biology
    2. Genetics and Genomics
    Federico A Vignale, Andrea Hernandez Garcia ... Adrian G Turjanski
    Research Article

    Yerba mate (YM, Ilex paraguariensis) is an economically important crop marketed for the elaboration of mate, the third-most widely consumed caffeine-containing infusion worldwide. Here, we report the first genome assembly of this species, which has a total length of 1.06 Gb and contains 53,390 protein-coding genes. Comparative analyses revealed that the large YM genome size is partly due to a whole-genome duplication (Ip-α) during the early evolutionary history of Ilex, in addition to the hexaploidization event (γ) shared by core eudicots. Characterization of the genome allowed us to clone the genes encoding methyltransferase enzymes that catalyse multiple reactions required for caffeine production. To our surprise, this species has converged upon a different biochemical pathway compared to that of coffee and tea. In order to gain insight into the structural basis for the convergent enzyme activities, we obtained a crystal structure for the terminal enzyme in the pathway that forms caffeine. The structure reveals that convergent solutions have evolved for substrate positioning because different amino acid residues facilitate a different substrate orientation such that efficient methylation occurs in the independently evolved enzymes in YM and coffee. While our results show phylogenomic constraint limits the genes coopted for convergence of caffeine biosynthesis, the X-ray diffraction data suggest structural constraints are minimal for the convergent evolution of individual reactions.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Angel D'Oliviera, Xuhang Dai ... Jeffrey S Mugridge
    Research Article

    The SARS-CoV-2 main protease (Mpro or Nsp5) is critical for production of viral proteins during infection and, like many viral proteases, also targets host proteins to subvert their cellular functions. Here, we show that the human tRNA methyltransferase TRMT1 is recognized and cleaved by SARS-CoV-2 Mpro. TRMT1 installs the N2,N2-dimethylguanosine (m2,2G) modification on mammalian tRNAs, which promotes cellular protein synthesis and redox homeostasis. We find that Mpro can cleave endogenous TRMT1 in human cell lysate, resulting in removal of the TRMT1 zinc finger domain. Evolutionary analysis shows the TRMT1 cleavage site is highly conserved in mammals, except in Muroidea, where TRMT1 is likely resistant to cleavage. TRMT1 proteolysis results in reduced tRNA binding and elimination of tRNA methyltransferase activity. We also determined the structure of an Mpro-TRMT1 peptide complex that shows how TRMT1 engages the Mpro active site in an uncommon substrate binding conformation. Finally, enzymology and molecular dynamics simulations indicate that kinetic discrimination occurs during a later step of Mpro-mediated proteolysis following substrate binding. Together, these data provide new insights into substrate recognition by SARS-CoV-2 Mpro that could help guide future antiviral therapeutic development and show how proteolysis of TRMT1 during SARS-CoV-2 infection impairs both TRMT1 tRNA binding and tRNA modification activity to disrupt host translation and potentially impact COVID-19 pathogenesis or phenotypes.